nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—MTHFR—cervical cancer	0.547	1	CbGaD
Methotrexate—ABCG2—Topotecan—cervical cancer	0.152	0.735	CbGbCtD
Methotrexate—ABCB1—Topotecan—cervical cancer	0.0549	0.265	CbGbCtD
Methotrexate—FOLR1—exocrine gland—cervical cancer	0.00548	0.0429	CbGeAlD
Methotrexate—SLC19A1—Metabolism of folate and pterines—MTHFR—cervical cancer	0.00438	0.0698	CbGpPWpGaD
Methotrexate—GGH—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.00421	0.0672	CbGpPWpGaD
Methotrexate—FPGS—Metabolism of folate and pterines—MTHFR—cervical cancer	0.00372	0.0594	CbGpPWpGaD
Methotrexate—Paresis—Topotecan—cervical cancer	0.00352	0.0684	CcSEcCtD
Methotrexate—GGH—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.00295	0.047	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism of folate and pterines—MTHFR—cervical cancer	0.0029	0.0463	CbGpPWpGaD
Methotrexate—FOLR1—epithelium—cervical cancer	0.00238	0.0187	CbGeAlD
Methotrexate—FOLR1—uterine cervix—cervical cancer	0.00236	0.0185	CbGeAlD
Methotrexate—Mucosal inflammation—Topotecan—cervical cancer	0.00232	0.0451	CcSEcCtD
Methotrexate—FOLR1—decidua—cervical cancer	0.00225	0.0176	CbGeAlD
Methotrexate—FOLR1—Folate Metabolism—MTHFR—cervical cancer	0.00223	0.0356	CbGpPWpGaD
Methotrexate—FOLR1—renal system—cervical cancer	0.00221	0.0173	CbGeAlD
Methotrexate—FOLR1—endometrium—cervical cancer	0.00214	0.0167	CbGeAlD
Methotrexate—Febrile neutropenia—Topotecan—cervical cancer	0.00213	0.0415	CcSEcCtD
Methotrexate—FOLR1—uterus—cervical cancer	0.00197	0.0154	CbGeAlD
Methotrexate—FPGS—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.00188	0.03	CbGpPWpGaD
Methotrexate—Folic Acid—MTHFR—cervical cancer	0.00185	0.5	CrCbGaD
Methotrexate—Tetrahydrofolic acid—MTHFR—cervical cancer	0.00185	0.5	CrCbGaD
Methotrexate—Interstitial lung disease—Topotecan—cervical cancer	0.00181	0.0353	CcSEcCtD
Methotrexate—Lung disorder—Topotecan—cervical cancer	0.00181	0.0353	CcSEcCtD
Methotrexate—FOLR1—female reproductive system—cervical cancer	0.00177	0.0139	CbGeAlD
Methotrexate—ABCC11—female reproductive system—cervical cancer	0.0017	0.0133	CbGeAlD
Methotrexate—Pleural effusion—Topotecan—cervical cancer	0.00168	0.0326	CcSEcCtD
Methotrexate—FOLR1—female gonad—cervical cancer	0.00161	0.0126	CbGeAlD
Methotrexate—GGH—uterine cervix—cervical cancer	0.00157	0.0123	CbGeAlD
Methotrexate—DHFR—Metabolism of folate and pterines—MTHFR—cervical cancer	0.00155	0.0248	CbGpPWpGaD
Methotrexate—SLC19A1—female reproductive system—cervical cancer	0.00155	0.0122	CbGeAlD
Methotrexate—ABCC11—female gonad—cervical cancer	0.00154	0.0121	CbGeAlD
Methotrexate—SLC46A1—decidua—cervical cancer	0.00152	0.0119	CbGeAlD
Methotrexate—ATIC—One Carbon Metabolism—MTHFR—cervical cancer	0.0015	0.024	CbGpPWpGaD
Methotrexate—GGH—decidua—cervical cancer	0.0015	0.0117	CbGeAlD
Methotrexate—Extravasation—Topotecan—cervical cancer	0.00147	0.0286	CcSEcCtD
Methotrexate—GGH—renal system—cervical cancer	0.00147	0.0115	CbGeAlD
Methotrexate—GGH—endometrium—cervical cancer	0.00142	0.0111	CbGeAlD
Methotrexate—Hyperbilirubinaemia—Topotecan—cervical cancer	0.00141	0.0274	CcSEcCtD
Methotrexate—GGH—mammalian vulva—cervical cancer	0.00137	0.0108	CbGeAlD
Methotrexate—ATIC—epithelium—cervical cancer	0.00135	0.0105	CbGeAlD
Methotrexate—FPGS—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.00132	0.021	CbGpPWpGaD
Methotrexate—FPGS—decidua—cervical cancer	0.00132	0.0103	CbGeAlD
Methotrexate—GGH—uterus—cervical cancer	0.00131	0.0102	CbGeAlD
Methotrexate—Respiratory failure—Topotecan—cervical cancer	0.00131	0.0254	CcSEcCtD
Methotrexate—SLCO4C1—renal system—cervical cancer	0.0013	0.0102	CbGeAlD
Methotrexate—Pulmonary embolism—Topotecan—cervical cancer	0.00128	0.025	CcSEcCtD
Methotrexate—SLCO4C1—endometrium—cervical cancer	0.00126	0.00986	CbGeAlD
Methotrexate—ATIC—renal system—cervical cancer	0.00125	0.00978	CbGeAlD
Methotrexate—FPGS—endometrium—cervical cancer	0.00125	0.00978	CbGeAlD
Methotrexate—SLCO4C1—mammalian vulva—cervical cancer	0.00122	0.00954	CbGeAlD
Methotrexate—FPGS—mammalian vulva—cervical cancer	0.00121	0.00946	CbGeAlD
Methotrexate—AOX1—Tryptophan metabolism—UBE3A—cervical cancer	0.00119	0.019	CbGpPWpGaD
Methotrexate—GGH—female reproductive system—cervical cancer	0.00118	0.00921	CbGeAlD
Methotrexate—Neoplasm—Topotecan—cervical cancer	0.00116	0.0226	CcSEcCtD
Methotrexate—GGH—Fluoropyrimidine Activity—TP53—cervical cancer	0.00112	0.0179	CbGpPWpGaD
Methotrexate—Sepsis—Topotecan—cervical cancer	0.00111	0.0217	CcSEcCtD
Methotrexate—ATIC—uterus—cervical cancer	0.00111	0.00871	CbGeAlD
Methotrexate—SLC46A1—female gonad—cervical cancer	0.00109	0.00852	CbGeAlD
Methotrexate—GGH—female gonad—cervical cancer	0.00107	0.00838	CbGeAlD
Methotrexate—GGH—vagina—cervical cancer	0.00106	0.00833	CbGeAlD
Methotrexate—SLC16A1—Cell surface interactions at the vascular wall—GP6—cervical cancer	0.00105	0.0167	CbGpPWpGaD
Methotrexate—SLCO1C1—renal system—cervical cancer	0.00104	0.00813	CbGeAlD
Methotrexate—FPGS—female reproductive system—cervical cancer	0.00103	0.0081	CbGeAlD
Methotrexate—SLC22A11—renal system—cervical cancer	0.00101	0.0079	CbGeAlD
Methotrexate—ATIC—female reproductive system—cervical cancer	0.001	0.00783	CbGeAlD
Methotrexate—SLC22A7—renal system—cervical cancer	0.000985	0.00771	CbGeAlD
Methotrexate—SLCO3A1—uterine cervix—cervical cancer	0.000976	0.00765	CbGeAlD
Methotrexate—DHFR—E2F transcription factor network—YY1—cervical cancer	0.000974	0.0155	CbGpPWpGaD
Methotrexate—Anaphylactoid reaction—Topotecan—cervical cancer	0.000963	0.0187	CcSEcCtD
Methotrexate—Lethargy—Topotecan—cervical cancer	0.000951	0.0185	CcSEcCtD
Methotrexate—SLCO4C1—vagina—cervical cancer	0.000944	0.00739	CbGeAlD
Methotrexate—FPGS—female gonad—cervical cancer	0.000941	0.00737	CbGeAlD
Methotrexate—FPGS—vagina—cervical cancer	0.000935	0.00733	CbGeAlD
Methotrexate—SLCO1B3—vagina—cervical cancer	0.000917	0.00718	CbGeAlD
Methotrexate—SLCO3A1—renal system—cervical cancer	0.000914	0.00715	CbGeAlD
Methotrexate—ATIC—female gonad—cervical cancer	0.00091	0.00713	CbGeAlD
Methotrexate—SLC19A1—lymph node—cervical cancer	0.000908	0.00711	CbGeAlD
Methotrexate—TYMS—uterine cervix—cervical cancer	0.000906	0.00709	CbGeAlD
Methotrexate—DHFR—uterine cervix—cervical cancer	0.000897	0.00702	CbGeAlD
Methotrexate—SLC19A1—Folate Metabolism—MTHFR—cervical cancer	0.000889	0.0142	CbGpPWpGaD
Methotrexate—MTHFR—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.000885	0.0141	CbGpPWpGaD
Methotrexate—PGD—uterine cervix—cervical cancer	0.000862	0.00675	CbGeAlD
Methotrexate—SLCO3A1—mammalian vulva—cervical cancer	0.000854	0.00669	CbGeAlD
Methotrexate—DHFR—decidua—cervical cancer	0.000854	0.00669	CbGeAlD
Methotrexate—TYMS—E2F transcription factor network—YY1—cervical cancer	0.00085	0.0136	CbGpPWpGaD
Methotrexate—FOLR1—Folate Metabolism—TP53—cervical cancer	0.000848	0.0135	CbGpPWpGaD
Methotrexate—DHFR—renal system—cervical cancer	0.000839	0.00657	CbGeAlD
Methotrexate—PGD—decidua—cervical cancer	0.000821	0.00643	CbGeAlD
Methotrexate—TYMS—endometrium—cervical cancer	0.000819	0.00641	CbGeAlD
Methotrexate—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000813	0.013	CbGpPWpGaD
Methotrexate—SLC16A1—epithelium—cervical cancer	0.000812	0.00636	CbGeAlD
Methotrexate—DHFR—endometrium—cervical cancer	0.000811	0.00635	CbGeAlD
Methotrexate—SLC22A11—female reproductive system—cervical cancer	0.000808	0.00633	CbGeAlD
Methotrexate—PGD—renal system—cervical cancer	0.000806	0.00631	CbGeAlD
Methotrexate—TYMS—mammalian vulva—cervical cancer	0.000792	0.0062	CbGeAlD
Methotrexate—DHFR—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.000786	0.0125	CbGpPWpGaD
Methotrexate—DHFR—mammalian vulva—cervical cancer	0.000784	0.00614	CbGeAlD
Methotrexate—PGD—endometrium—cervical cancer	0.00078	0.0061	CbGeAlD
Methotrexate—SLC16A1—decidua—cervical cancer	0.000767	0.006	CbGeAlD
Methotrexate—Pancytopenia—Topotecan—cervical cancer	0.000765	0.0149	CcSEcCtD
Methotrexate—AOX1—uterine cervix—cervical cancer	0.000759	0.00595	CbGeAlD
Methotrexate—PGD—mammalian vulva—cervical cancer	0.000754	0.00591	CbGeAlD
Methotrexate—Neutropenia—Topotecan—cervical cancer	0.000753	0.0146	CcSEcCtD
Methotrexate—SLC16A1—renal system—cervical cancer	0.000753	0.0059	CbGeAlD
Methotrexate—DHFR—uterus—cervical cancer	0.000747	0.00585	CbGeAlD
Methotrexate—MTHFR—female reproductive system—cervical cancer	0.000744	0.00582	CbGeAlD
Methotrexate—ABCC10—uterine cervix—cervical cancer	0.000739	0.00579	CbGeAlD
Methotrexate—SLCO1B1—renal system—cervical cancer	0.000732	0.00573	CbGeAlD
Methotrexate—SLCO3A1—female reproductive system—cervical cancer	0.000732	0.00573	CbGeAlD
Methotrexate—SLC16A1—endometrium—cervical cancer	0.000728	0.0057	CbGeAlD
Methotrexate—AOX1—decidua—cervical cancer	0.000724	0.00567	CbGeAlD
Methotrexate—Pneumonia—Topotecan—cervical cancer	0.000723	0.014	CcSEcCtD
Methotrexate—PGD—uterus—cervical cancer	0.000718	0.00563	CbGeAlD
Methotrexate—Infestation—Topotecan—cervical cancer	0.000718	0.014	CcSEcCtD
Methotrexate—Infestation NOS—Topotecan—cervical cancer	0.000718	0.014	CcSEcCtD
Methotrexate—SLC19A1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cervical cancer	0.000713	0.0114	CbGpPWpGaD
Methotrexate—AOX1—renal system—cervical cancer	0.00071	0.00556	CbGeAlD
Methotrexate—ABCC3—decidua—cervical cancer	0.000708	0.00554	CbGeAlD
Methotrexate—ABCC10—decidua—cervical cancer	0.000704	0.00551	CbGeAlD
Methotrexate—Stomatitis—Topotecan—cervical cancer	0.0007	0.0136	CcSEcCtD
Methotrexate—SLC46A1—lymph node—cervical cancer	0.0007	0.00548	CbGeAlD
Methotrexate—ABCC3—renal system—cervical cancer	0.000695	0.00544	CbGeAlD
Methotrexate—ABCC10—renal system—cervical cancer	0.000691	0.00541	CbGeAlD
Methotrexate—Sweating—Topotecan—cervical cancer	0.000689	0.0134	CcSEcCtD
Methotrexate—GGH—lymph node—cervical cancer	0.000688	0.00539	CbGeAlD
Methotrexate—AOX1—endometrium—cervical cancer	0.000687	0.00538	CbGeAlD
Methotrexate—TYMS—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.000686	0.0109	CbGpPWpGaD
Methotrexate—Hepatobiliary disease—Topotecan—cervical cancer	0.000679	0.0132	CcSEcCtD
Methotrexate—TYMS—female reproductive system—cervical cancer	0.000679	0.00531	CbGeAlD
Methotrexate—Epistaxis—Topotecan—cervical cancer	0.000678	0.0132	CcSEcCtD
Methotrexate—MTHFR—female gonad—cervical cancer	0.000677	0.0053	CbGeAlD
Methotrexate—DHFR—female reproductive system—cervical cancer	0.000672	0.00526	CbGeAlD
Methotrexate—SLC16A1—uterus—cervical cancer	0.000671	0.00525	CbGeAlD
Methotrexate—ABCC10—endometrium—cervical cancer	0.000669	0.00523	CbGeAlD
Methotrexate—SLCO3A1—female gonad—cervical cancer	0.000666	0.00521	CbGeAlD
Methotrexate—AOX1—mammalian vulva—cervical cancer	0.000664	0.0052	CbGeAlD
Methotrexate—SLC22A7—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.000663	0.0106	CbGpPWpGaD
Methotrexate—SLCO3A1—vagina—cervical cancer	0.000662	0.00518	CbGeAlD
Methotrexate—Haemoglobin—Topotecan—cervical cancer	0.000648	0.0126	CcSEcCtD
Methotrexate—ABCC10—mammalian vulva—cervical cancer	0.000647	0.00506	CbGeAlD
Methotrexate—PGD—female reproductive system—cervical cancer	0.000646	0.00506	CbGeAlD
Methotrexate—Haemorrhage—Topotecan—cervical cancer	0.000645	0.0125	CcSEcCtD
Methotrexate—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000644	0.0103	CbGpPWpGaD
Methotrexate—Pharyngitis—Topotecan—cervical cancer	0.00064	0.0124	CcSEcCtD
Methotrexate—AOX1—uterus—cervical cancer	0.000633	0.00496	CbGeAlD
Methotrexate—DHFR—One Carbon Metabolism—MTHFR—cervical cancer	0.000627	0.01	CbGpPWpGaD
Methotrexate—TYMS—female gonad—cervical cancer	0.000617	0.00483	CbGeAlD
Methotrexate—ABCC10—uterus—cervical cancer	0.000616	0.00482	CbGeAlD
Methotrexate—TYMS—vagina—cervical cancer	0.000614	0.00481	CbGeAlD
Methotrexate—DHFR—female gonad—cervical cancer	0.000611	0.00479	CbGeAlD
Methotrexate—DHFR—vagina—cervical cancer	0.000608	0.00476	CbGeAlD
Methotrexate—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cervical cancer	0.000606	0.00967	CbGpPWpGaD
Methotrexate—FPGS—lymph node—cervical cancer	0.000605	0.00474	CbGeAlD
Methotrexate—SLC16A1—female reproductive system—cervical cancer	0.000603	0.00472	CbGeAlD
Methotrexate—SLCO1A2—renal system—cervical cancer	0.000596	0.00467	CbGeAlD
Methotrexate—SLC46A1—Folate Metabolism—MTHFR—cervical cancer	0.000589	0.0094	CbGpPWpGaD
Methotrexate—PGD—female gonad—cervical cancer	0.000588	0.0046	CbGeAlD
Methotrexate—SLCO1B1—female reproductive system—cervical cancer	0.000587	0.00459	CbGeAlD
Methotrexate—ATIC—lymph node—cervical cancer	0.000585	0.00458	CbGeAlD
Methotrexate—Angiopathy—Topotecan—cervical cancer	0.000585	0.0114	CcSEcCtD
Methotrexate—PGD—vagina—cervical cancer	0.000584	0.00457	CbGeAlD
Methotrexate—Immune system disorder—Topotecan—cervical cancer	0.000582	0.0113	CcSEcCtD
Methotrexate—Mediastinal disorder—Topotecan—cervical cancer	0.000581	0.0113	CcSEcCtD
Methotrexate—Chills—Topotecan—cervical cancer	0.000579	0.0112	CcSEcCtD
Methotrexate—ABCC4—renal system—cervical cancer	0.000574	0.00449	CbGeAlD
Methotrexate—Alopecia—Topotecan—cervical cancer	0.00057	0.0111	CcSEcCtD
Methotrexate—SLC22A8—renal system—cervical cancer	0.000569	0.00446	CbGeAlD
Methotrexate—AOX1—female reproductive system—cervical cancer	0.000569	0.00446	CbGeAlD
Methotrexate—ABCC3—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.000568	0.00906	CbGpPWpGaD
Methotrexate—DHFR—Trans-sulfuration and one carbon metabolism—MTHFR—cervical cancer	0.000564	0.00899	CbGpPWpGaD
Methotrexate—Malnutrition—Topotecan—cervical cancer	0.000561	0.0109	CcSEcCtD
Methotrexate—ABCC3—female reproductive system—cervical cancer	0.000556	0.00436	CbGeAlD
Methotrexate—ABCC2—renal system—cervical cancer	0.000555	0.00435	CbGeAlD
Methotrexate—ABCC10—female reproductive system—cervical cancer	0.000554	0.00434	CbGeAlD
Methotrexate—DHFR—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.00055	0.00877	CbGpPWpGaD
Methotrexate—SLC16A1—female gonad—cervical cancer	0.000549	0.0043	CbGeAlD
Methotrexate—TYMS—One Carbon Metabolism—MTHFR—cervical cancer	0.000547	0.00873	CbGpPWpGaD
Methotrexate—Back pain—Topotecan—cervical cancer	0.000543	0.0106	CcSEcCtD
Methotrexate—ABCC4—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.000534	0.00852	CbGpPWpGaD
Methotrexate—ABCC1—uterine cervix—cervical cancer	0.000523	0.00409	CbGeAlD
Methotrexate—Ill-defined disorder—Topotecan—cervical cancer	0.000521	0.0101	CcSEcCtD
Methotrexate—Anaemia—Topotecan—cervical cancer	0.000519	0.0101	CcSEcCtD
Methotrexate—AOX1—female gonad—cervical cancer	0.000518	0.00405	CbGeAlD
Methotrexate—AOX1—vagina—cervical cancer	0.000515	0.00403	CbGeAlD
Methotrexate—ABCC4—uterus—cervical cancer	0.000511	0.004	CbGeAlD
Methotrexate—ABCC3—female gonad—cervical cancer	0.000506	0.00397	CbGeAlD
Methotrexate—Malaise—Topotecan—cervical cancer	0.000506	0.00984	CcSEcCtD
Methotrexate—ABCC10—female gonad—cervical cancer	0.000504	0.00395	CbGeAlD
Methotrexate—Leukopenia—Topotecan—cervical cancer	0.000502	0.00977	CcSEcCtD
Methotrexate—ABCC10—vagina—cervical cancer	0.000501	0.00392	CbGeAlD
Methotrexate—FPGS—Fluoropyrimidine Activity—TP53—cervical cancer	0.0005	0.00797	CbGpPWpGaD
Methotrexate—ABCC1—decidua—cervical cancer	0.000498	0.0039	CbGeAlD
Methotrexate—TYMS—Trans-sulfuration and one carbon metabolism—MTHFR—cervical cancer	0.000492	0.00785	CbGpPWpGaD
Methotrexate—Cough—Topotecan—cervical cancer	0.00049	0.00952	CcSEcCtD
Methotrexate—SLCO1C1—lymph node—cervical cancer	0.000487	0.00381	CbGeAlD
Methotrexate—TYMS—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.00048	0.00766	CbGpPWpGaD
Methotrexate—Chest pain—Topotecan—cervical cancer	0.000478	0.00929	CcSEcCtD
Methotrexate—Myalgia—Topotecan—cervical cancer	0.000478	0.00929	CcSEcCtD
Methotrexate—Arthralgia—Topotecan—cervical cancer	0.000478	0.00929	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000475	0.00922	CcSEcCtD
Methotrexate—ABCC1—endometrium—cervical cancer	0.000473	0.0037	CbGeAlD
Methotrexate—SLC46A1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cervical cancer	0.000472	0.00753	CbGpPWpGaD
Methotrexate—Discomfort—Topotecan—cervical cancer	0.000472	0.00918	CcSEcCtD
Methotrexate—SLC22A7—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.000463	0.00739	CbGpPWpGaD
Methotrexate—ABCC4—female reproductive system—cervical cancer	0.000459	0.0036	CbGeAlD
Methotrexate—Anaphylactic shock—Topotecan—cervical cancer	0.000458	0.0089	CcSEcCtD
Methotrexate—ABCC1—mammalian vulva—cervical cancer	0.000457	0.00358	CbGeAlD
Methotrexate—Infection—Topotecan—cervical cancer	0.000455	0.00885	CcSEcCtD
Methotrexate—Nervous system disorder—Topotecan—cervical cancer	0.000449	0.00873	CcSEcCtD
Methotrexate—Thrombocytopenia—Topotecan—cervical cancer	0.000449	0.00872	CcSEcCtD
Methotrexate—Skin disorder—Topotecan—cervical cancer	0.000445	0.00865	CcSEcCtD
Methotrexate—ABCC2—female reproductive system—cervical cancer	0.000445	0.00348	CbGeAlD
Methotrexate—Hyperhidrosis—Topotecan—cervical cancer	0.000443	0.00861	CcSEcCtD
Methotrexate—Anorexia—Topotecan—cervical cancer	0.000437	0.00849	CcSEcCtD
Methotrexate—ABCC1—uterus—cervical cancer	0.000436	0.00341	CbGeAlD
Methotrexate—MTHFR—lymph node—cervical cancer	0.000435	0.00341	CbGeAlD
Methotrexate—ABCG2—uterine cervix—cervical cancer	0.000433	0.00339	CbGeAlD
Methotrexate—SLCO3A1—lymph node—cervical cancer	0.000428	0.00335	CbGeAlD
Methotrexate—ABCC4—female gonad—cervical cancer	0.000418	0.00327	CbGeAlD
Methotrexate—Musculoskeletal discomfort—Topotecan—cervical cancer	0.000417	0.00811	CcSEcCtD
Methotrexate—ABCG2—decidua—cervical cancer	0.000412	0.00323	CbGeAlD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.000412	0.00657	CbGpPWpGaD
Methotrexate—Paraesthesia—Topotecan—cervical cancer	0.000411	0.008	CcSEcCtD
Methotrexate—Dyspnoea—Topotecan—cervical cancer	0.000408	0.00794	CcSEcCtD
Methotrexate—Dyspepsia—Topotecan—cervical cancer	0.000403	0.00784	CcSEcCtD
Methotrexate—Decreased appetite—Topotecan—cervical cancer	0.000398	0.00774	CcSEcCtD
Methotrexate—ABCC3—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.000397	0.00634	CbGpPWpGaD
Methotrexate—TYMS—lymph node—cervical cancer	0.000397	0.00311	CbGeAlD
Methotrexate—Gastrointestinal disorder—Topotecan—cervical cancer	0.000396	0.00769	CcSEcCtD
Methotrexate—Fatigue—Topotecan—cervical cancer	0.000395	0.00768	CcSEcCtD
Methotrexate—DHFR—lymph node—cervical cancer	0.000393	0.00308	CbGeAlD
Methotrexate—Pain—Topotecan—cervical cancer	0.000392	0.00761	CcSEcCtD
Methotrexate—ABCG2—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.000392	0.00625	CbGpPWpGaD
Methotrexate—ABCG2—endometrium—cervical cancer	0.000391	0.00307	CbGeAlD
Methotrexate—ABCG2—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.000388	0.00618	CbGpPWpGaD
Methotrexate—ABCG2—mammalian vulva—cervical cancer	0.000379	0.00296	CbGeAlD
Methotrexate—PGD—lymph node—cervical cancer	0.000378	0.00296	CbGeAlD
Methotrexate—Feeling abnormal—Topotecan—cervical cancer	0.000378	0.00734	CcSEcCtD
Methotrexate—Gastrointestinal pain—Topotecan—cervical cancer	0.000375	0.00728	CcSEcCtD
Methotrexate—ABCC4—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.000373	0.00596	CbGpPWpGaD
Methotrexate—Urticaria—Topotecan—cervical cancer	0.000364	0.00707	CcSEcCtD
Methotrexate—Abdominal pain—Topotecan—cervical cancer	0.000362	0.00704	CcSEcCtD
Methotrexate—Body temperature increased—Topotecan—cervical cancer	0.000362	0.00704	CcSEcCtD
Methotrexate—ABCG2—uterus—cervical cancer	0.000361	0.00282	CbGeAlD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.00036	0.00574	CbGpPWpGaD
Methotrexate—ABCC1—female gonad—cervical cancer	0.000356	0.00279	CbGeAlD
Methotrexate—ABCC1—vagina—cervical cancer	0.000354	0.00277	CbGeAlD
Methotrexate—SLC16A1—lymph node—cervical cancer	0.000353	0.00276	CbGeAlD
Methotrexate—SLC19A1—Folate Metabolism—TP53—cervical cancer	0.000338	0.00539	CbGpPWpGaD
Methotrexate—Hypersensitivity—Topotecan—cervical cancer	0.000338	0.00656	CcSEcCtD
Methotrexate—AOX1—lymph node—cervical cancer	0.000333	0.00261	CbGeAlD
Methotrexate—Asthenia—Topotecan—cervical cancer	0.000329	0.00639	CcSEcCtD
Methotrexate—ABCC3—lymph node—cervical cancer	0.000326	0.00255	CbGeAlD
Methotrexate—Pruritus—Topotecan—cervical cancer	0.000324	0.0063	CcSEcCtD
Methotrexate—ABCC10—lymph node—cervical cancer	0.000324	0.00254	CbGeAlD
Methotrexate—DHFR—Folate Metabolism—MTHFR—cervical cancer	0.000316	0.00504	CbGpPWpGaD
Methotrexate—Diarrhoea—Topotecan—cervical cancer	0.000313	0.00609	CcSEcCtD
Methotrexate—Dizziness—Topotecan—cervical cancer	0.000303	0.00589	CcSEcCtD
Methotrexate—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000303	0.00483	CbGpPWpGaD
Methotrexate—ABCG2—female gonad—cervical cancer	0.000295	0.00231	CbGeAlD
Methotrexate—ABCG2—vagina—cervical cancer	0.000293	0.0023	CbGeAlD
Methotrexate—Vomiting—Topotecan—cervical cancer	0.000291	0.00566	CcSEcCtD
Methotrexate—TYMS—Circadian rythm related genes—UBE3A—cervical cancer	0.000291	0.00464	CbGpPWpGaD
Methotrexate—Rash—Topotecan—cervical cancer	0.000289	0.00561	CcSEcCtD
Methotrexate—Dermatitis—Topotecan—cervical cancer	0.000289	0.00561	CcSEcCtD
Methotrexate—Headache—Topotecan—cervical cancer	0.000287	0.00558	CcSEcCtD
Methotrexate—SLC16A1—Hemostasis—SERPIND1—cervical cancer	0.000285	0.00454	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—GP6—cervical cancer	0.000285	0.00454	CbGpPWpGaD
Methotrexate—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cervical cancer	0.000278	0.00444	CbGpPWpGaD
Methotrexate—ALB—lymph node—cervical cancer	0.000278	0.00217	CbGeAlD
Methotrexate—ABCG2—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.000274	0.00437	CbGpPWpGaD
Methotrexate—Nausea—Topotecan—cervical cancer	0.000272	0.00529	CcSEcCtD
Methotrexate—ABCC4—lymph node—cervical cancer	0.000269	0.0021	CbGeAlD
Methotrexate—ABCC2—lymph node—cervical cancer	0.00026	0.00204	CbGeAlD
Methotrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cervical cancer	0.000253	0.00404	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—GP5—cervical cancer	0.000249	0.00397	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000247	0.00394	CbGpPWpGaD
Methotrexate—MTHFR—Fluoropyrimidine Activity—TP53—cervical cancer	0.000235	0.00375	CbGpPWpGaD
Methotrexate—ABCC1—lymph node—cervical cancer	0.000229	0.00179	CbGeAlD
Methotrexate—SLC46A1—Folate Metabolism—TP53—cervical cancer	0.000224	0.00357	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—WNT2—cervical cancer	0.00022	0.00351	CbGpPWpGaD
Methotrexate—ABCB1—epithelium—cervical cancer	0.000215	0.00169	CbGeAlD
Methotrexate—ABCB1—uterine cervix—cervical cancer	0.000213	0.00167	CbGeAlD
Methotrexate—ABCC4—Hemostasis—GP6—cervical cancer	0.000212	0.00338	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—SERPIND1—cervical cancer	0.000212	0.00338	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.00021	0.00334	CbGpPWpGaD
Methotrexate—DHFR—Fluoropyrimidine Activity—TP53—cervical cancer	0.000209	0.00333	CbGpPWpGaD
Methotrexate—ABCB1—decidua—cervical cancer	0.000203	0.00159	CbGeAlD
Methotrexate—ABCB1—renal system—cervical cancer	0.0002	0.00156	CbGeAlD
Methotrexate—ABCB1—endometrium—cervical cancer	0.000193	0.00151	CbGeAlD
Methotrexate—ABCG2—lymph node—cervical cancer	0.00019	0.00149	CbGeAlD
Methotrexate—FPGS—Disease—WNT2—cervical cancer	0.000187	0.00299	CbGpPWpGaD
Methotrexate—ABCB1—mammalian vulva—cervical cancer	0.000187	0.00146	CbGeAlD
Methotrexate—ALB—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.000186	0.00297	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—GP5—cervical cancer	0.000185	0.00296	CbGpPWpGaD
Methotrexate—TYMS—Fluoropyrimidine Activity—TP53—cervical cancer	0.000182	0.00291	CbGpPWpGaD
Methotrexate—ABCB1—uterus—cervical cancer	0.000178	0.00139	CbGeAlD
Methotrexate—SLC22A7—Fluoropyrimidine Activity—TP53—cervical cancer	0.000176	0.00281	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—CA9—cervical cancer	0.000174	0.00278	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—WNT5A—cervical cancer	0.000167	0.00266	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.000163	0.0026	CbGpPWpGaD
Methotrexate—ABCB1—female reproductive system—cervical cancer	0.00016	0.00125	CbGeAlD
Methotrexate—ABCG2—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.000157	0.0025	CbGpPWpGaD
Methotrexate—ABCC3—Fluoropyrimidine Activity—TP53—cervical cancer	0.000151	0.00241	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—CA9—cervical cancer	0.000148	0.00236	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—CA9—cervical cancer	0.000148	0.00236	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—WNT2—cervical cancer	0.000146	0.00233	CbGpPWpGaD
Methotrexate—ABCB1—female gonad—cervical cancer	0.000145	0.00114	CbGeAlD
Methotrexate—ABCB1—vagina—cervical cancer	0.000145	0.00113	CbGeAlD
Methotrexate—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cervical cancer	0.000143	0.00229	CbGpPWpGaD
Methotrexate—FPGS—Disease—WNT5A—cervical cancer	0.000142	0.00226	CbGpPWpGaD
Methotrexate—ABCC4—Fluoropyrimidine Activity—TP53—cervical cancer	0.000142	0.00226	CbGpPWpGaD
Methotrexate—MTHFR—Folate Metabolism—TP53—cervical cancer	0.000135	0.00215	CbGpPWpGaD
Methotrexate—PGD—Disease—WNT2—cervical cancer	0.000133	0.00213	CbGpPWpGaD
Methotrexate—DHFR—Folate Metabolism—TP53—cervical cancer	0.00012	0.00191	CbGpPWpGaD
Methotrexate—ALB—Vitamin B12 Metabolism—MTHFR—cervical cancer	0.000119	0.0019	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—CA9—cervical cancer	0.000115	0.00184	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—HLA-DPB1—cervical cancer	0.000113	0.0018	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—WNT5A—cervical cancer	0.000111	0.00176	CbGpPWpGaD
Methotrexate—PGD—Metabolism—CA9—cervical cancer	0.000106	0.00168	CbGpPWpGaD
Methotrexate—ABCG2—Fluoropyrimidine Activity—TP53—cervical cancer	0.000104	0.00166	CbGpPWpGaD
Methotrexate—PGD—Disease—WNT5A—cervical cancer	0.000101	0.00161	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—MTHFR—cervical cancer	9.7e-05	0.00155	CbGpPWpGaD
Methotrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—cervical cancer	9.61e-05	0.00153	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—HES1—cervical cancer	9.6e-05	0.00153	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—GP6—cervical cancer	9.6e-05	0.00153	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SERPIND1—cervical cancer	9.6e-05	0.00153	CbGpPWpGaD
Methotrexate—ABCB1—lymph node—cervical cancer	9.35e-05	0.000732	CbGeAlD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	9.22e-05	0.00147	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—HLA-DQB1—cervical cancer	8.82e-05	0.00141	CbGpPWpGaD
Methotrexate—MTHFR—Disease—WNT2—cervical cancer	8.8e-05	0.0014	CbGpPWpGaD
Methotrexate—AOX1—Disease—WNT2—cervical cancer	8.6e-05	0.00137	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—TERT—cervical cancer	8.48e-05	0.00135	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—MTHFR—cervical cancer	8.44e-05	0.00135	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—TERT—cervical cancer	8.41e-05	0.00134	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—GP5—cervical cancer	8.39e-05	0.00134	CbGpPWpGaD
Methotrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—cervical cancer	8.39e-05	0.00134	CbGpPWpGaD
Methotrexate—FPGS—Disease—HES1—cervical cancer	8.17e-05	0.0013	CbGpPWpGaD
Methotrexate—DHFR—Disease—WNT2—cervical cancer	7.82e-05	0.00125	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—FGFR3—cervical cancer	7.72e-05	0.00123	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—MTHFR—cervical cancer	7.71e-05	0.00123	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	7.61e-05	0.00121	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—NOTCH1—cervical cancer	7.25e-05	0.00116	CbGpPWpGaD
Methotrexate—FPGS—Disease—MTHFR—cervical cancer	7.17e-05	0.00114	CbGpPWpGaD
Methotrexate—FPGS—Disease—TERT—cervical cancer	7.15e-05	0.00114	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—MTHFR—cervical cancer	7.07e-05	0.00113	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	6.97e-05	0.00111	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—CA9—cervical cancer	6.96e-05	0.00111	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—CA9—cervical cancer	6.8e-05	0.00108	CbGpPWpGaD
Methotrexate—ABCC4—Ectoderm Differentiation—CTNNB1—cervical cancer	6.78e-05	0.00108	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	6.72e-05	0.00107	CbGpPWpGaD
Methotrexate—MTHFR—Disease—WNT5A—cervical cancer	6.67e-05	0.00106	CbGpPWpGaD
Methotrexate—FPGS—Disease—FGFR3—cervical cancer	6.57e-05	0.00105	CbGpPWpGaD
Methotrexate—AOX1—Disease—WNT5A—cervical cancer	6.52e-05	0.00104	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—HES1—cervical cancer	6.36e-05	0.00101	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—CA9—cervical cancer	6.19e-05	0.000987	CbGpPWpGaD
Methotrexate—FPGS—Disease—NOTCH1—cervical cancer	6.16e-05	0.000984	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—MTHFR—cervical cancer	6.01e-05	0.000959	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—MTHFR—cervical cancer	6.01e-05	0.000959	CbGpPWpGaD
Methotrexate—DHFR—Disease—WNT5A—cervical cancer	5.93e-05	0.000946	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TERT—cervical cancer	5.83e-05	0.00093	CbGpPWpGaD
Methotrexate—PGD—Disease—HES1—cervical cancer	5.82e-05	0.000928	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—CASP8—cervical cancer	5.76e-05	0.000919	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—CA9—cervical cancer	5.63e-05	0.000899	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—MTHFR—cervical cancer	5.59e-05	0.000892	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—TERT—cervical cancer	5.57e-05	0.000889	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—MTOR—cervical cancer	5.43e-05	0.000867	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—CD4—cervical cancer	5.42e-05	0.000865	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CA9—cervical cancer	5.4e-05	0.000861	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	5.33e-05	0.00085	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—FGFR3—cervical cancer	5.12e-05	0.000816	CbGpPWpGaD
Methotrexate—PGD—Disease—MTHFR—cervical cancer	5.11e-05	0.000816	CbGpPWpGaD
Methotrexate—PGD—Disease—TERT—cervical cancer	5.1e-05	0.000813	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TERT—cervical cancer	5.08e-05	0.000811	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CA9—cervical cancer	4.95e-05	0.00079	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—CTNNB1—cervical cancer	4.82e-05	0.000768	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—NOTCH1—cervical cancer	4.8e-05	0.000766	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—MTHFR—cervical cancer	4.68e-05	0.000747	CbGpPWpGaD
Methotrexate—PGD—Disease—FGFR3—cervical cancer	4.68e-05	0.000746	CbGpPWpGaD
Methotrexate—FPGS—Disease—MTOR—cervical cancer	4.62e-05	0.000737	CbGpPWpGaD
Methotrexate—FPGS—Disease—CD4—cervical cancer	4.61e-05	0.000736	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	4.47e-05	0.000713	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CA9—cervical cancer	4.47e-05	0.000713	CbGpPWpGaD
Methotrexate—ABCC1—Disease—WNT2—cervical cancer	4.43e-05	0.000706	CbGpPWpGaD
Methotrexate—PGD—Disease—NOTCH1—cervical cancer	4.39e-05	0.000701	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—CASP3—cervical cancer	4.36e-05	0.000696	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—TP53—cervical cancer	4.29e-05	0.000685	CbGpPWpGaD
Methotrexate—PGD—Metabolism—MTHFR—cervical cancer	4.28e-05	0.000683	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—STAT3—cervical cancer	4.2e-05	0.00067	CbGpPWpGaD
Methotrexate—FPGS—Disease—CTNNB1—cervical cancer	4.1e-05	0.000653	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CA9—cervical cancer	3.89e-05	0.000621	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HES1—cervical cancer	3.84e-05	0.000612	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—EGFR—cervical cancer	3.82e-05	0.000609	CbGpPWpGaD
Methotrexate—AOX1—Disease—HES1—cervical cancer	3.75e-05	0.000598	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—TP53—cervical cancer	3.68e-05	0.000588	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—MTOR—cervical cancer	3.6e-05	0.000574	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—CD4—cervical cancer	3.59e-05	0.000573	CbGpPWpGaD
Methotrexate—FPGS—Disease—STAT3—cervical cancer	3.57e-05	0.00057	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CA9—cervical cancer	3.5e-05	0.000559	CbGpPWpGaD
Methotrexate—DHFR—Disease—HES1—cervical cancer	3.41e-05	0.000544	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TERT—cervical cancer	3.36e-05	0.000537	CbGpPWpGaD
Methotrexate—ABCC1—Disease—WNT5A—cervical cancer	3.35e-05	0.000535	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CA9—cervical cancer	3.33e-05	0.000531	CbGpPWpGaD
Methotrexate—AOX1—Disease—MTHFR—cervical cancer	3.29e-05	0.000526	CbGpPWpGaD
Methotrexate—PGD—Disease—MTOR—cervical cancer	3.29e-05	0.000525	CbGpPWpGaD
Methotrexate—AOX1—Disease—TERT—cervical cancer	3.29e-05	0.000524	CbGpPWpGaD
Methotrexate—PGD—Disease—CD4—cervical cancer	3.29e-05	0.000524	CbGpPWpGaD
Methotrexate—FPGS—Disease—EGFR—cervical cancer	3.24e-05	0.000518	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—CTNNB1—cervical cancer	3.19e-05	0.000509	CbGpPWpGaD
Methotrexate—MTHFR—Disease—FGFR3—cervical cancer	3.09e-05	0.000492	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CA9—cervical cancer	3.08e-05	0.000491	CbGpPWpGaD
Methotrexate—AOX1—Disease—FGFR3—cervical cancer	3.01e-05	0.000481	CbGpPWpGaD
Methotrexate—DHFR—Disease—MTHFR—cervical cancer	3e-05	0.000478	CbGpPWpGaD
Methotrexate—DHFR—Disease—TERT—cervical cancer	2.99e-05	0.000477	CbGpPWpGaD
Methotrexate—PGD—Disease—CTNNB1—cervical cancer	2.92e-05	0.000466	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NOTCH1—cervical cancer	2.9e-05	0.000462	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	2.84e-05	0.000454	CbGpPWpGaD
Methotrexate—AOX1—Disease—NOTCH1—cervical cancer	2.83e-05	0.000452	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—STAT3—cervical cancer	2.78e-05	0.000444	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—MTHFR—cervical cancer	2.76e-05	0.00044	CbGpPWpGaD
Methotrexate—DHFR—Disease—FGFR3—cervical cancer	2.74e-05	0.000438	CbGpPWpGaD
Methotrexate—DHFR—Disease—NOTCH1—cervical cancer	2.58e-05	0.000411	CbGpPWpGaD
Methotrexate—PGD—Disease—STAT3—cervical cancer	2.54e-05	0.000406	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—EGFR—cervical cancer	2.53e-05	0.000403	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—MTHFR—cervical cancer	2.51e-05	0.0004	CbGpPWpGaD
Methotrexate—PGD—Disease—EGFR—cervical cancer	2.31e-05	0.000369	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—MTHFR—cervical cancer	2.29e-05	0.000365	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—cervical cancer	2.22e-05	0.000354	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—MTHFR—cervical cancer	2.19e-05	0.000349	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MTOR—cervical cancer	2.17e-05	0.000346	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CD4—cervical cancer	2.17e-05	0.000346	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	2.15e-05	0.000343	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—cervical cancer	2.14e-05	0.000342	CbGpPWpGaD
Methotrexate—AOX1—Disease—MTOR—cervical cancer	2.12e-05	0.000338	CbGpPWpGaD
Methotrexate—AOX1—Disease—CD4—cervical cancer	2.12e-05	0.000338	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	2.07e-05	0.000331	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—MTHFR—cervical cancer	2.01e-05	0.000321	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—cervical cancer	1.94e-05	0.000309	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HES1—cervical cancer	1.93e-05	0.000308	CbGpPWpGaD
Methotrexate—DHFR—Disease—MTOR—cervical cancer	1.93e-05	0.000308	CbGpPWpGaD
Methotrexate—DHFR—Disease—CD4—cervical cancer	1.93e-05	0.000307	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CTNNB1—cervical cancer	1.93e-05	0.000307	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CA9—cervical cancer	1.9e-05	0.000303	CbGpPWpGaD
Methotrexate—AOX1—Disease—CTNNB1—cervical cancer	1.88e-05	0.0003	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—MTHFR—cervical cancer	1.81e-05	0.000289	CbGpPWpGaD
Methotrexate—DHFR—Disease—CTNNB1—cervical cancer	1.71e-05	0.000273	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MTHFR—cervical cancer	1.7e-05	0.000271	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TERT—cervical cancer	1.69e-05	0.00027	CbGpPWpGaD
Methotrexate—MTHFR—Disease—STAT3—cervical cancer	1.68e-05	0.000268	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CA9—cervical cancer	1.67e-05	0.000266	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	1.64e-05	0.000262	CbGpPWpGaD
Methotrexate—AOX1—Disease—STAT3—cervical cancer	1.64e-05	0.000262	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—cervical cancer	1.6e-05	0.000255	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—MTHFR—cervical cancer	1.58e-05	0.000252	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FGFR3—cervical cancer	1.55e-05	0.000248	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EGFR—cervical cancer	1.53e-05	0.000243	CbGpPWpGaD
Methotrexate—DHFR—Disease—STAT3—cervical cancer	1.49e-05	0.000238	CbGpPWpGaD
Methotrexate—AOX1—Disease—EGFR—cervical cancer	1.49e-05	0.000238	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOTCH1—cervical cancer	1.46e-05	0.000233	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—MTHFR—cervical cancer	1.42e-05	0.000227	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.38e-05	0.00022	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—cervical cancer	1.36e-05	0.000216	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—MTHFR—cervical cancer	1.35e-05	0.000215	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—MTHFR—cervical cancer	1.25e-05	0.000199	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MTOR—cervical cancer	1.09e-05	0.000174	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CD4—cervical cancer	1.09e-05	0.000174	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CTNNB1—cervical cancer	9.68e-06	0.000154	CbGpPWpGaD
Methotrexate—ABCC1—Disease—STAT3—cervical cancer	8.44e-06	0.000135	CbGpPWpGaD
Methotrexate—ALB—Metabolism—MTHFR—cervical cancer	7.71e-06	0.000123	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—cervical cancer	7.67e-06	0.000122	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—cervical cancer	7.22e-06	0.000115	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MTHFR—cervical cancer	6.76e-06	0.000108	CbGpPWpGaD
